检索结果-南通市图书馆

Chemotherapy and molecular targeting therapy for recurrent cervical cancer

Chinese Journal of Cancer Research 2016年第2期28卷 241-253页

作者： Naotake Tsuda Hidemichi Watari Kimio Ushijima Department of Obstetrics and Gynecology Kurume University School of Medicine Kurume Japan Department of Obstetrics and Gynecology Hokkaido University Graduate School of Medicine Sapporo Japan

For patients with primary stage IVB, persistent, or recurrent cervical cancer, chemotherapy remains the standard treatment, although it is neither curative nor associated with long-term disease control. In this review, we summarized the history of treatment of recurrent cervical cancer, and the current recommendation for chemotherapy and molecular targeted therapy. Eligible articles were identified by a search of the MEDLINE bibliographical database for the period up to November 30, 2014. The search strategy included the following any or all of the keywords：＂uterine cervical cancer＂, ＂chemotherapy＂, and ＂targeted therapies＂. Since cisplatin every 21 days was considered as the historical standard treatment for recurrent cervical cancer, subsequent trials have evaluated and demonstrated activity for other agents including paclitaxel, gemcitabine, topotecan and vinorelbine among others. Accordingly, promising agents were incorporated into phase III trials. To examine the best agent to combine with cisplatin, several landmark phase III clinical trials were conducted by Gynecologic Oncology Group （GOG） and Japan Clinical Oncology Group （JCOG）. Through, GOG204 and JCOG0505, paclitaxel/cisplatin （TP） and paclitaxel/carboplatin （TC） are now considered to be the recommended therapies for recurrent cervical cancer patients. However, the prognosis of patients who are already resistant to chemotherapy, are very poor. Therefore new therapeutic strategies are urgently required. molecular targeted therapy will be the most hopeful candidate of these strategies. From the results of GOG240, bevacizumab combined with TP reached its primary endpoint of improving overall survival （OS）. Although, the prognosis for recurrent cervical cancer patients is still poor, the results of GOG240 shed light on the usefulness of molecular target agents to chemotherapy in cancer patients. Recurrent cervical cancer is generally considered incurable and current chemotherapy regiments offer only modest

关键词： Cervical cancer chemotherapy molecular targeting therapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Hyaluronic acid-based dual-responsive nanomicelles mediated mutually synergistic photothermal and molecular targeting therapies

引用

Nano Research 2022年第7期15卷 6361-6371页

作者： Liangliang Cai Ronghua Ni Xiaofei Ma Rongrong Huang Zhiyuan Tang Jinqiu Xu Yong Han Yuehua Guo Zhifeng Gu Department of Pharmacy Affiliated Hospital of Nantong UniversityNantong 226001China Department of Radiation Oncology Affiliated Hospital of Nantong UniversityNantong 226001China Research Center of Clinical Medicine Affiliated Hospital of Nantong UniversityNantong 226001China Department of Rheumatology Affiliated Hospital of Nantong UniversityNantong 226001China

Precise clinical treatment of triple-negative breast cancer(TNBC)is an obstacle in ***-assisted photothermal therapy(PTT)is a superior treatment modality for TNBC in terms of ***,thermoresistance arising from PTT and insufficient drug release from nanocarriers decrease the efficacy of ***13387 is a novel HSP90 inhibitor that can weaken thermoresistance and undergoing clinic II phase study,showing satisfactory antitumour activity through molecularly targeted therapy(MTT).Whereas,it has poor *** hyaluronic acid and stearic acid were connected by hydrazone bonds and disulfide bonds,forming an amphipathic copolymer that could self-assembled into nanomicelles,followed by encapsulating Cypate and *** nanomicelles exhibited great features,including achieving mutually synergistic PTT/MTT for overcoming thermoresistance and promoting translocation of drugs,increasing the solubility of Cypate and AT13387,showing a pH/redox dual response that contributes to drug release,and having the ability of active ***,the nanomicelles developed in this study may be a promising strategy for the precise treatment of TNBC.

关键词： hyaluronic acid nanomicelles dual responsive photothermal therapy molecular targeting therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

molecular targeting to treat gastric cancer

引用

World Journal of Gastroenterology 2014年第38期20卷 13741-13755页

作者： Keishiro Aoyagi Kikuo Kouhuji Junya Kizaki Taro Isobe Kousuke Hashimoto Kazuo Shirouzu Department of Surgery Kurume University School of Medicine

Trastuzumab that targets human epidermal growth factor receptor 2 (HER2) protein is the only approved molecular targeting agent for treating gastric cancer in Japan and the outcomes have been favorable. However, trastuzumab is effective for only 10% to 20% of the population with gastric cancer that expresses HER2 protein. molecular targeting therapy with bevacizumab against vascular endothelial growth factors (VEGF) and with cetuximab and panitumumab against the epidermal growth factors pathway that have been approved for treating colorectal cancer are not considered effective for treating gastric cancer according to several clinical trials. However, ramucirumab that targets VEGF receptor-2 prolonged overall survival in a large phase III clinical trial and it might be an effective molecular targeting therapy for gastric cancer. The significance of molecular targeting therapy for gastric cancer remains controversial. A large-scale randomized clinical trial of novel molecular targeting agents with which to treat gastric cancer is needed.

关键词： Gastric cancer molecular targeting therapy Human epidermal growth factor receptor 2 protein Vascular endothelial growth factors/Vascular endothelial growth factor receptor pathway Epidermal growth factors pathway

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nestin:A novel angiogenesis marker and possible target for tumor angiogenesis

引用

World Journal of Gastroenterology 2013年第1期19卷 42-48页

作者： Yoko Matsuda Masahito Hagio Toshiyuki Ishiwata Departments of Pathology and Integrative Oncological Pathology Nippon Medical SchoolTokyo 113-8602Japan

Abnormal vasculature,termed tumor vessels,is a hallmark of solid *** degree of angiogenesis is associated with tumor aggressiveness and clinical ***,exact quantification of tumor vessels is useful to evaluate ***,selective detection of newly formed tumor vessels within cancer tissues using specific markers raises the possibility of molecular targeted therapy via the inhibition of tumor ***,an intermediate filament protein,is reportedly expressed in repair processes,various neoplasms,and proliferating vascular endothelial *** expression is detected in endothelial cells of embryonic capillaries,capillaries of the corpus luteum,which replenishes itself by angiogenesis,and proliferating endothelial progenitor cells,but not in mature endothelial ***,expression of nestin is relatively limited to proliferating vascular endothelial cells and endothelial progenitor *** expression is also reported in blood vessels within glioblastoma,prostate cancer,colorectal cancer,and pancreatic cancer,and its expression is more specific for newly formed blood vessels than other endothelial cell ***-positive blood vessels form smaller vessels with high proliferation activity in *** of nestin in vascular endothelial cells suppresses endothelial cell growth and tumor formation ability of pancreatic cancers in *** nestin to more accurately evaluate microvessel density in cancer specimens may be a novel prognostic ***,nestin-targeted therapy may suppress tumor proliferation via inhibition of angiogenesis in numerous malignancies,including pancreatic *** this review article,we focus on nestin as a novel angiogenesis marker and possible therapeutic target via inhibition of tumor angiogenesis.

关键词： Nestin Angiogenesis molecular targeting therapy Gastrointestinal cancer Pancreatic cancer Microvessel density CD34 CD31 Factor VIII

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：